RECOMBINATE 500 IU

País: Israel

Idioma: anglès

Font: Ministry of Health

ingredients actius:

COAGULATION FACTOR VIII RECOMBINANT 500 IU/VIAL

Disponible des:

TEVA MEDICAL MARKETING LTD.

Codi ATC:

B02BD05

formulario farmacéutico:

POWDER FOR SOLUTION FOR INJECTION

Vía de administración:

I.V

Fabricat per:

BAXTER S.A., BELGIUM

Grupo terapéutico:

COAGULATION FACTOR VII

indicaciones terapéuticas:

The use of Recombinate is indicated in the treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). Recombinate is also indicated in the perioperative management of patients with haemophilia A. Recombinate is appropriate for use in children of all ages including the newborn. (Safety and efficacy studies have been performed in both previously treated and previously untreated children). The product in not suitable for the treatment of von Willebrand's disease.

Data d'autorització:

2010-07-01